UK markets closed

Xvivo Perfusion AB (publ) (0RKL.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
521.79+11.25 (+2.20%)
At close: 05:34PM BST
Currency in SEK

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 2.07
52-week change 316.62%
S&P500 52-week change 324.13%
52-week high 3528.00
52-week low 3205.50
50-day moving average 3291.55
200-day moving average 3282.98

Share statistics

Avg vol (3-month) 39.84k
Avg vol (10-day) 34.45k
Shares outstanding 526.4M
Implied shares outstanding 6N/A
Float 825M
% held by insiders 110.48%
% held by institutions 156.01%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 Jun 2024

Profitability

Profit margin 17.28%
Operating margin (ttm)15.89%

Management effectiveness

Return on assets (ttm)1.32%
Return on equity (ttm)6.84%

Income statement

Revenue (ttm)698.72M
Revenue per share (ttm)22.72
Quarterly revenue growth (yoy)36.10%
Gross profit (ttm)N/A
EBITDA 64.86M
Net income avi to common (ttm)120.74M
Diluted EPS (ttm)0.24
Quarterly earnings growth (yoy)294.90%

Balance sheet

Total cash (mrq)480.77M
Total cash per share (mrq)15.26
Total debt (mrq)27.19M
Total debt/equity (mrq)1.34%
Current ratio (mrq)4.13
Book value per share (mrq)64.28

Cash flow statement

Operating cash flow (ttm)69.3M
Levered free cash flow (ttm)-77.76M